Vaxxas
About Vaxxas
Products & Services
Specialties
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: Series D Equity and Debt Financing T: - FT: Series D Equity and Debt Financing |
A: 59000000 MR: - FA: A$90 million FAN: 59000000 |
D: 2025-08-25 FD: 2025-08-25 |
4 investors |
| 2 |
RT: Program Funding T: - FT: Program Funding |
A: 4800000 MR: - FA: US$4.8 million FAN: 4800000 |
D: 2025-01-22 FD: 2025-01-22 |
1 investors |
| 3 |
RT: Grant T: - FT: Grant |
A: 3670000 MR: - FA: US$3.67 million FAN: 3670000 |
D: 2023-08-23 FD: 2023-08-23 |
1 investors |
Growth Metrics
Team & Leadership
David Peacock
Chief Executive Officer
Angus Forster
Chief Technology Officer
Scott Fry
Chief Operating Officer
Tom Lake
Chief Business Officer
Melanie Farris
Chief Corporate Affairs Officer
Deborah Pascoe
Senior Vice President - CMC Development
Recent News
Vaxxas Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Key Competitors
Competitor Alpha
Series B · $50M raised
Competitor Beta
Series C · $120M raised
Competitor Gamma
Series A · $25M raised
Competitor Delta
Seed · $10M raised
Company Details
- Website
- vaxxas.com
- Industries
- Healthcare/Biotechnology
- Company Size
- ~380 employees (est.)
Similar Companies
Discover AI-powered company recommendations based on industry, funding, and team profiles.
Upgrade to ProTechnology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro